Presentation is loading. Please wait.

Presentation is loading. Please wait.

Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large.

Published byAva Chessher Modified over 10 years ago

Similar presentations

Presentation on theme: "Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large."— Presentation transcript:

1 Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large Side Branch. The Nordic-Baltic Bifurcation Study IV Indulis Kumsars, Matti Niemelä, Andrejs Erglis, Kari Kervinen, Evald H. Christiansen, Michael Maeng, Andis Dombrovskis, Vytautas Abraitis, Aleksandras Kibarskis, Terje K. Steigen, Thor Trovik, Gustavs Latkovskis, Dace Sondore, Inga Narbute, Christian Juhl Terkelsen, Markku Eskola, Hannu Romppanen, Per Thayssen, Anne Kaltoft,Tuija Vasankari, Pål Gunnes, Ole Frobert, Fredrik Calais, Juha Hartikainen, Svend Eggert Jensen, Thomas Engstrøm, Niels R. Holm, Jens F. Lassen and Leif Thuesen For the Nordic-Baltic PCI Study Group

2 Disclosure Statement of Financial Interest I, Indulis Kumsars, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. The Nordic-Baltic Bifurcation IV Study was an academic study primarily funded by participating hospitals. The participating institutions received unrestricted study grants form Cordis and Abbot.

3 Nordic-Baltic Bifurcation Study IV Participating Centers Denmark Aarhus University Hospital (112 pts) Aalborg University Hospital (13 pts) Odense University Hospital (10 pts) Rigshospitalet Copenhagen (3 pts) Latvia P.Stradins University Hospital, Riga (159 pts) Sweden Örebro Hospital (11 pts) Linköping (3 pts) Karolinska University Hospital (1 pts) Finland Oulu University Hospital (75 pts) Tampere University Hospital (8 pts) Turku University Hospital (6 pts) Kuopio University Hospital (2 pt) Norway Tromsø University Hospital (18pts) Arendal Hospital (3 pts) Feiring Heart Clinic (2 pts) Lithuania Vilnius University Hospital (21 pts) The Nordic-Baltic PCI Study Group

4 Background Provisional (simple) stenting is the preferred strategy in treatment of most bifurcation lesions It is unknown if this also applies to true bifurcation lesions involving a large side branch Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

5 Aim To compare provisional stenting and two- stent techniques for the treatment of true coronary bifurcation lesions involving a large side branch Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

6 Hypothesis Two stent techniques are superior to provisional stenting in treatment of true coronary bifurcation lesions involving a large side branch Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

7 Methods Open label, randomized, multicenter trial 1:1 randomization Clinical FU at 0, 1 and 6 months Angiographic substudy with 8 months FU Study stents: –Sirolimus eluting Cordis Cypher Select+ (first 225 patients) –Everolimus eluting Abbott Xience V (last 225 patients) Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

8 Primary endpoint Combined endpoint after 6 months: cardiac death non-index procedure related myocardial infarction TLR definite stent thrombosis Nordic-Baltic Bifurcation Study IV

9 Individual endpoints of: Total death Cardiac death Non-index procedure related MI Target lesion revascularization (TLR) Target vessel revascularization (TVR) Definite stent thrombosis Procedure related myocardial infarction 8-month angiographic follow-up results Secondary endpoints Nordic-Baltic Bifurcation Study IV

10 Methods Inclusion criteria Age≥18 Stable Angina, UAP, NSTEMI MV≥3.0mm SB ≥2.75mm Bifurcation stenosis involving both MV and SB (≥50%DS by eyeballing) Exclusion criteria STEMI Cardiogenic shock Other critical illness Relevant allergies Cr ≥ 200 µmol/L SB lesion length >15mm Nordic-Baltic Bifurcation Study IV

11 Implantation techniques Provisional SB stenting –Two wires –Predilatation –MV stenting –If TIMI flow 75%DS in ostial SB: kissing balloon dilatation –If SB TIMI flow <III after kissing balloon dilatation, SB stenting using a T- or Culotte technique Nordic-Baltic Bifurcation Study IV

12 Implantation techniques Two-stent techniques –Two wires –Predilatation of segments to be stented –Culotte stenting recommended T-stenting and mini-crush allowed –Final kissing balloon dilatation Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

13 Patient flowchart Nordic Baltic Bifurcation study IV n=450 Provisional SB stening n=221* Two stent n=229* 1 lost to FU 1 excluded due to protocol violation Provisional Completed 6M FU n=220 Two stent Completed 6M FU n=227 1 withdrawal *numbers not balanced due to block randomization and sites with less than 4 inclusions Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

14 Baseline clinical characteristics Provisional (n=221) Two-stent (n=229) p Age (yrs)64±1263±11ns Diabetes (%)16.315.3ns Active smoking (%)19.121.1ns Statin treatment (%)81.881.1ns Hypertension (%)70.065.6ns Family history (%)50.747.4ns History of PCI (%)35.533.5ns History of CABG (%)3.61.8ns Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

15 Lesion characteristics Provisional (n=221) Two-stent (n=229) p LAD/diagonal (%)74.176.7ns CX/obtuse marginal (%)16.817.6ns RCA PDA/PLA (%)6.44.0ns LM/LAD/CX (%)2.71.3ns Ref. diameter main vessel (mm)*3.53.40.04 Ref. diameter side branch (mm)*2.9 ns Lesion length SB (mm)*7.48.0<0.0001 Angulation > 60-70° (%)*50.951.1ns * visual estimation Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

16 Procedural data Provisional (n=221) Two-stent (n=229) p SB dilatation (%)64.378.0- SB dilation or final kissing (%)78.7-- Final kissing balloon dilatation (%)36.191.2- SB stented (%)3.796.0- Culotte-65.6- T-stent-7.0- Other-26.4- Tx succesful* (%)97.799.1ns * (Residual stenosis <30% of MV + TIMI flow III in SB) Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

17 Procedural data Provisional (n=221) Two-stent (n=229) p Procedure time (min)73.992.6<0.0001 Contrast volume (mL)187238<0.0001 Flouroscopy time (min)14.022.8<0.0001 Tx succesful* (%)97.799.1ns Procedural CK-MB>5x UPL** (%)3.03.1ns Procedural CK-MB>3x UPL** (%)6.06.1ns * Residual stenosis <30% of MV + TIMI flow III in SB ** Assessment possible in 327 patients Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

18 Eventfree survival curve at 6 months 4.6% 1.8% p=0.09 Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

19 Individual endpoints at 6 months Provisional (n=220) Two-stent (n=227) p Total death (%)00.40.32 Cardiac death (%)00- Non-procedural myocardial infarction (%) 1.80.90.50 Stent thrombosis (%)0.90.40.54 Target lesion revascularization (%)3.21.30.18 Target vessel revascularization (%)3.71.30.11 Angina CCS class ≥ II2.71.30.39 Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

20 Conclusion After 6 months, two-stent techniques for treatment of true bifurcation lesions with a large side branch showed no significant difference in MACE rate compared to provisional side branch stenting Longer and more complex procedures in the two- stent group did not translate into more procedural myocardial infarctions Recommendations on optimal strategy for this lesion subset should await longer term follow-up Nordic-Baltic Bifurcation Study IV The Nordic-Baltic PCI Study Group

Download ppt "Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large."

Similar presentations

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.
A Prospective, Randomized, All-Comers Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting.

A Prospective, Randomized, "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting.
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Jens Flensted.

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Jens Flensted.
Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions The Nordic Bifurcation Stent.

Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions The Nordic Bifurcation Stent.
BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.

BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
BIFURCATION LESIONS Dr. Tahsin.N

BIFURCATION LESIONS Dr. Tahsin.N
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.

Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,

Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I

29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.

Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.

Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.

BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
For the Nordic-Baltic PCI Study Group

For the Nordic-Baltic PCI Study Group
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
1 of 18 90671521 Presented by Gregg W. Stone, MD, ACC 2011. PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

Similar presentations

Ads by Google